[{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"1823a066-42ab-41e9-bc3a-b338ae379009","acronym":"ORACLE","url":"https://clinicaltrials.gov/study/NCT06817174","created_at":"2025-02-25T14:12:17.340Z","updated_at":"2025-02-25T14:12:17.340Z","phase":"","brief_title":"Ovarian Cancer Radiomics Approach in CT Led Evaluation","source_id_and_acronym":"NCT06817174 - ORACLE","lead_sponsor":"Imperial College Healthcare NHS Trust","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 01/01/2032","primary_completion_date":" 01/01/2032","study_txt":" Completion: 01/01/2032","study_completion_date":" 01/01/2032","last_update_posted":"2025-02-19"},{"id":"cedde79c-686f-4afe-89d0-1fd3a8d96cf4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05200260","created_at":"2022-01-20T14:53:41.699Z","updated_at":"2025-02-25T14:38:18.943Z","phase":"Phase 2","brief_title":"Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","source_id_and_acronym":"NCT05200260","lead_sponsor":"Shanghai Gynecologic Oncology Group","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • docetaxel • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"d42429d0-899b-4f9f-a9fd-c90fa6b9a50e","acronym":"NRG-GY027","url":"https://clinicaltrials.gov/study/NCT05276973","created_at":"2022-03-14T14:54:04.422Z","updated_at":"2025-02-25T16:38:53.900Z","phase":"Phase 1","brief_title":"Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05276973 - NRG-GY027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1","pipe":" | ","alterations":" HRD","tags":["PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-07"},{"id":"8ba4b2c4-2d3e-460e-9a2f-77116f701fa8","acronym":"S1513","url":"https://clinicaltrials.gov/study/NCT02890355","created_at":"2021-01-18T14:11:10.280Z","updated_at":"2025-02-25T16:36:47.130Z","phase":"Phase 2","brief_title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02890355 - S1513","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CEACAM5","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"70895122-f43e-478e-b06c-44c96910d6ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265872","created_at":"2021-04-20T09:53:17.764Z","updated_at":"2025-02-25T16:44:48.890Z","phase":"Phase 1","brief_title":"Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","source_id_and_acronym":"NCT04265872","lead_sponsor":"Baylor Research Institute","biomarkers":" ER • HRD","pipe":" | ","alterations":" HRD • ER negative","tags":["ER • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-05"},{"id":"b72b0a64-54a8-4a42-8b82-b948a538ae47","acronym":"CAPRI","url":"https://clinicaltrials.gov/study/NCT03462342","created_at":"2021-01-18T17:04:00.829Z","updated_at":"2025-02-25T14:58:45.950Z","phase":"Phase 2","brief_title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03462342 - CAPRI","lead_sponsor":"University of Pennsylvania","biomarkers":" HRD • BRCA • MUC16","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"a170957e-b723-496d-b981-b2bbe36c4fc4","acronym":"EFFORT","url":"https://clinicaltrials.gov/study/NCT03579316","created_at":"2021-01-18T17:36:17.068Z","updated_at":"2025-02-25T17:29:43.272Z","phase":"Phase 2","brief_title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03579316 - EFFORT","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/07/2018","start_date":" 12/07/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-30"},{"id":"b8e5058b-32bb-4610-b262-21974b89110e","acronym":"SL03-OHD-101","url":"https://clinicaltrials.gov/study/NCT04406623","created_at":"2021-01-18T21:14:44.896Z","updated_at":"2025-02-25T17:30:15.356Z","phase":"Phase 1","brief_title":"Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer","source_id_and_acronym":"NCT04406623 - SL03-OHD-101","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 02/02/2023","study_completion_date":" 02/02/2023","last_update_posted":"2025-01-30"},{"id":"66081ec9-8bfe-411c-9d59-68a619e9fe86","acronym":"SCOUT-1","url":"https://clinicaltrials.gov/study/NCT04830709","created_at":"2021-04-05T13:53:00.171Z","updated_at":"2025-02-25T17:37:04.458Z","phase":"","brief_title":"Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer","source_id_and_acronym":"NCT04830709 - SCOUT-1","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2025-01-29"},{"id":"6b8fc966-3ab9-41b6-9e44-57638a4042ab","acronym":"DUO-O","url":"https://clinicaltrials.gov/study/NCT03737643","created_at":"2021-01-18T18:18:25.912Z","updated_at":"2025-02-25T17:36:10.253Z","phase":"Phase 3","brief_title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","source_id_and_acronym":"NCT03737643 - DUO-O","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1407","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/30/2028","study_completion_date":" 03/30/2028","last_update_posted":"2025-01-29"},{"id":"04a57d4f-2959-452c-80a6-f0212d657b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04992013","created_at":"2021-08-05T13:53:09.751Z","updated_at":"2025-02-25T13:12:43.122Z","phase":"Phase 2","brief_title":"Niraparib in Tumors Metastatic to the CNS","source_id_and_acronym":"NCT04992013","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3","pipe":" | ","alterations":" HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/05/2022","start_date":" 04/05/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"dfa37710-8128-4c60-aefe-7507a106a2e0","acronym":"MK3475-A53","url":"https://clinicaltrials.gov/study/NCT05379972","created_at":"2022-05-18T11:57:02.291Z","updated_at":"2025-02-25T16:17:42.708Z","phase":"Phase 2","brief_title":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","source_id_and_acronym":"NCT05379972 - MK3475-A53","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4","pipe":" | ","alterations":" HRD","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-26"},{"id":"9306dfb7-3366-4bae-b67b-1347cc62c160","acronym":"SALVOVAR","url":"https://clinicaltrials.gov/study/NCT06476184","created_at":"2025-02-26T14:20:08.949Z","updated_at":"2025-02-26T14:20:08.949Z","phase":"Phase 3","brief_title":"Utility of Adjusting Chemotherapy Dose \u0026 Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery","source_id_and_acronym":"NCT06476184 - SALVOVAR","lead_sponsor":"ARCAGY/ GINECO GROUP","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA wild-type • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 08/05/2024","start_date":" 08/05/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-11-18"},{"id":"94fc6139-3248-47b5-b7ab-1c8fcba69d09","acronym":"KEYNOTE-F86","url":"https://clinicaltrials.gov/study/NCT05787587","created_at":"2023-03-28T14:05:08.346Z","updated_at":"2025-02-25T16:18:41.344Z","phase":"Phase 1","brief_title":"A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05787587 - KEYNOTE-F86","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IDE161"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-10-28"},{"id":"3ab273df-ad84-463e-809d-9cbd385707ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990803","created_at":"2023-08-14T14:10:30.823Z","updated_at":"2025-02-25T15:36:27.652Z","phase":"Phase 2","brief_title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","source_id_and_acronym":"NCT05990803","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/06/2023","start_date":" 11/06/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-10-24"},{"id":"2b33007a-0dee-4baa-8c83-5d27c6932cf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05659914","created_at":"2023-12-28T15:17:11.723Z","updated_at":"2025-02-25T15:00:45.040Z","phase":"Phase 2","brief_title":"Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations","source_id_and_acronym":"NCT05659914","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" HRD • RAD51","pipe":" | ","alterations":" HRD","tags":["HRD • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-10-18"},{"id":"bcf70251-d41c-4f2f-a5ab-42c88ec7efb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06622798","created_at":"2025-02-26T15:01:15.365Z","updated_at":"2025-02-26T15:01:15.365Z","phase":"","brief_title":"Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients","source_id_and_acronym":"NCT06622798","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 08/20/2024","start_date":" 08/20/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/07/2026","study_completion_date":" 07/07/2026","last_update_posted":"2024-10-02"},{"id":"9938550f-8e02-48a0-9be9-a575ea84f10a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02677038","created_at":"2021-01-18T13:03:11.604Z","updated_at":"2025-02-25T14:57:29.913Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Stage IV Pancreatic Cancer","source_id_and_acronym":"NCT02677038","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • ATM • HRD • BRCA • RAD51","pipe":" | ","alterations":" HRD • ATM mutation • BRCA mutation","tags":["BRCA1 • ATM • HRD • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2024-10-01"},{"id":"4eebcb86-b74a-47b2-a056-569deb93926e","acronym":"FLAME","url":"https://clinicaltrials.gov/study/NCT05775549","created_at":"2023-03-20T20:03:29.333Z","updated_at":"2025-02-25T16:18:40.170Z","phase":"","brief_title":"A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer","source_id_and_acronym":"NCT05775549 - FLAME","lead_sponsor":"AstraZeneca","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2023","study_completion_date":" 10/27/2023","last_update_posted":"2024-09-20"},{"id":"066af9ab-9fbe-40c8-8b39-9e712dd6f439","acronym":"","url":"https://clinicaltrials.gov/study/NCT06600841","created_at":"2025-02-26T13:35:01.576Z","updated_at":"2025-02-26T13:35:01.576Z","phase":"Phase 2","brief_title":"Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer","source_id_and_acronym":"NCT06600841","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HRD","pipe":" | ","alterations":" PD-L1 expression • HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-09-19"},{"id":"1c16003b-285a-46dd-9a81-5650057a4b2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04336943","created_at":"2021-01-18T20:59:44.586Z","updated_at":"2025-02-25T14:59:00.006Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load","source_id_and_acronym":"NCT04336943","lead_sponsor":"University of Washington","biomarkers":" BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" MSI-H/dMMR • HRD","tags":["BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 06/06/2025","study_completion_date":" 06/06/2025","last_update_posted":"2024-07-02"},{"id":"7f306611-7670-46f5-9d82-2776f52be9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633239","created_at":"2022-11-25T17:57:43.239Z","updated_at":"2024-07-02T16:34:37.807Z","phase":"Phase 1","brief_title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04633239","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • HRD • CCNE1 • BRCA • CASP3","pipe":" | ","alterations":" HRD","tags":["BRCA1 • HRD • CCNE1 • BRCA • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"543cd16b-633b-4c4e-b967-73fb1131c4b4","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT03845296","created_at":"2021-01-17T17:13:03.964Z","updated_at":"2024-07-02T16:34:59.337Z","phase":"Phase 2","brief_title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT03845296 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation","tags":["EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"}]